| 臺大學術典藏 |
2021-04-29T05:09:03Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.; Ho C.-C.; Hsia T.-C.; Tseng J.-S.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Chang G.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:02Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
|
Chih-Hsin Yang;Camidge D.R.;Yang C.-T.;Zhou J.;Guo R.;Chiu C.-H.;Chang G.-C.;Shiah H.-S.;Chen Y.;Wang C.-C.;Berz D.;Su W.-C.;Yang N.;Wang Z.;Fang J.;Chen J.;Nikolinakos P.;Lu Y.;Pan H.;Maniam A.;Bazhenova L.;Shirai K.;Jahanzeb M.;Willis M.;Masood N.;Chowhan N.;Hsia T.-C.;Jian H.;Lu S.; CHIH-HSIN YANG; Camidge D.R.; Yang C.-T.; Zhou J.; Guo R.; Chiu C.-H.; Chang G.-C.; Shiah H.-S.; Chen Y.; Wang C.-C.; Berz D.; Su W.-C.; Yang N.; Wang Z.; Fang J.; Chen J.; Nikolinakos P.; Lu Y.; Pan H.; Maniam A.; Bazhenova L.; Shirai K.; Jahanzeb M.; Willis M.; Masood N.; Chowhan N.; Hsia T.-C.; Jian H.; Lu S. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
|
Wu Y.-L.;Cheng Y.;Zhou J.;Lu S.;Zhang Y.;Zhao J.;Kim D.-W.;Soo R.A.;Kim S.-W.;Pan H.;Chen Y.-M.;Chian C.-F.;Liu X.;Tan D.S.W.;Bruns R.;Straub J.;Johne A.;Scheele J.;Park K.;Chih-Hsin Yang;Liu Z.;Chen X.;Wang M.;Yu S.;Zhang H.;Fang J.;Li W.;Yang C.-H.;Chang G.-C.;Hsia T.-C.;Yang C.-T.;Wang C.-C.;Cho B.C.;Lee K.H.;Kim Y.-C.;An H.J.;Woo I.S.;Cho J.Y.;Shin S.W.;Lee J.-S.;Kim J.-H.;Yoo S.S.;Kato T.;Shinagawa N.;Tan S.W.D.;Ngo L.S.-M.;Ratnavelu K.;Ahmad A.R.;Liam C.K.;De Marinis F.;Tassone P.;Molla A.I.;Calles Blanco A.;Lazaro Quintela M.E.;Felip Font E.;Dingemans A.-M.;Bui L.; Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. |
| 臺大學術典藏 |
2021-04-23T05:56:24Z |
Lung Cancer in Republic of China
|
Luo Y.-H.;Chiu C.-H.;Scott Kuo C.-H.;Chou T.-Y.;Yeh Y.-C.;Hsu H.-S.;Yen S.-H.;Wu Y.-H.;Chih-Hsin Yang;Liao B.-C.;Hsia T.-C.;Chen Y.-M.; Luo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; CHIH-HSIN YANG; Liao B.-C.; Hsia T.-C.; Chen Y.-M. |
| 臺大學術典藏 |
2021-03-11T08:34:19Z |
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
|
Wei Y.-F.;Huang W.-T.;Liu T.-C.;Shieh J.-M.;Chian C.-F.;Wu M.-F.;Chang C.-C.;Lin C.-H.;Jen-Chang Ko;Lin C.-M.;Hsia T.-C.; Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHANG KO; Lin C.-M.; Hsia T.-C. |
| 臺大學術典藏 |
2021-03-11T08:29:33Z |
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
|
Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHANG KO; Lin C.-M.; Hsia T.-C. |
| 臺大學術典藏 |
2021-03-11T07:58:28Z |
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
|
Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHANG KO; Lin C.-M.; Hsia T.-C. |
| 國立成功大學 |
2021 |
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study
|
Huang, Y.-H.;Hung, J.-Y.;Ko, H.-W.;Su, P.-L.;Lai, C.-L.;Chang, H.-C.;Hsia, T.-C.;Lin, S.-H.;Wu, K.-L.;Yang, C.-T.;Su, W.-C.;Chu, Y.-C.;Wang, C.-C.;Liao, W.-Y.;Lin, Y.-T.;Lin, C.-H.;Lin, M.-C.;Hsu, K.-H.;Tseng, J.-S.;Yang, T.-Y.;Chen, K.-C.;Lee, M.-H.;Yu, S.-L.;Ho, C.-C.;Chang, G.-C. |
| 國立成功大學 |
2021 |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
Yang, J.C.-H.;Reckamp, K.L.;Kim, Y.-C.;Novello, S.;Smit, E.F.;Lee, J.-S.;Su, W.-C.;Akerley, W.L.;Blakely, C.M.;Groen, H.J.M.;Bazhenova, L.;Carcereny, Costa E.;Chiari, R.;Hsia, T.-C.;Golsorkhi, T.;Despain, Despain D.;Shih, D.;Popat, S.;Wakelee, H. |
